Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
post
Last Updated on: 22 May, 2024|Author: Getaka | Social: X Twitter Profile
Stock Ticker - BSE: 542934 | NSE: CBPL

Fundamental Analysis of Chandra Bhagat Pharma Ltd

Basic Stock Data

Last Updated: May 22, 2024, 7:00 pm

Market Cap 89.7 Cr.
Current Price 119
High / Low160/80.0
Stock P/E76.7
Book Value 37.3
Dividend Yield0.00 %
ROCE7.13 %
ROE3.36 %
Face Value 10.0
PEG Ratio2.52

Data Source: screener.in

Competitors of Chandra Bhagat Pharma Ltd

Stock NameMarket CapCurrent PriceHigh / LowStock P/EBook ValueDividend YieldROCEROEFace Value
Glenmark Pharmaceuticals Ltd 28,887 Cr. 1,0251,098/587233 3310.24 %14.2 %5.44 % 1.00
Glaxosmithkline Pharmaceuticals Ltd 40,161 Cr. 2,3712,650/1,28758.1 1051.35 %54.1 %39.3 % 10.0
Astrazeneca Pharma India Ltd 12,859 Cr. 5,1447,221/3,09880.6 2620.31 %30.9 %23.0 % 2.00
Sanofi India Ltd 20,533 Cr. 8,9169,380/6,31036.2 4411.87 %71.1 %51.5 % 10.0
Bafna Pharmaceuticals Ltd 209 Cr. 88.5126/75.918.6 34.80.00 %15.9 %16.4 % 10.0
Industry Average20,529.80 Cr3,508.9085.30234.760.75%37.24%27.13%6.60

Quarterly Result

MonthSep 2020Mar 2021Sep 2021Mar 2022Sep 2022Mar 2023Sep 2023
Sales224843514475119
Expenses214742504374124
Operating Profit222112-5
OPM %7%3%4%2%2%2%-4%
Other Income0001107
Interest2212111
Depreciation0000000
Profit before tax0011111
Tax %25%33%24%31%31%15%32%
Net Profit0000011
EPS in Rs0.040.210.570.480.490.720.83

Last Updated: May 11, 2024, 11:56 am

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: April 27, 2024, 1:31 am

MonthMar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023TTM
Sales20354861809097106947194120195
Expenses19354658768592102916791116198
Operating Profit102334553433-3
OPM %7%1%4%5%4%5%5%4%3%5%3%3%-2%
Other Income0010001000207
Interest1022344434322
Depreciation0000000000001
Profit before tax0001112100112
Tax %-135%27%17%39%51%27%33%22%26%32%27%22%
Net Profit0000011100111
EPS in Rs16.009.608.3710.298.3715.7924.6410.290.410.251.061.211.55
Dividend Payout %0%0%0%0%0%0%0%0%0%0%0%0%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year2017-20182018-20192019-20202022-2023
YoY Net Profit Growth (%)0.00%0.00%-100.00%0.00%
Change in YoY Net Profit Growth (%)0.00%0.00%-100.00%100.00%

Growth

Compounded Sales Growth
10 Years:13%
5 Years:4%
3 Years:8%
TTM:104%
Compounded Profit Growth
10 Years:14%
5 Years:-2%
3 Years:43%
TTM:60%
Stock Price CAGR
10 Years:%
5 Years:%
3 Years:35%
1 Year:-15%
Return on Equity
10 Years:4%
5 Years:3%
3 Years:2%
Last Year:3%

Last Updated: May 22, 2024, 8:57 am

Balance Sheet

Last Updated: April 23, 2024, 12:08 pm

MonthMar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Sep 2023
Equity Capital0000000188888
Reserves3366678141818192021
Borrowings11111928282222313027211918
Other Liabilities9978102628371919251414
Total Liabilities22243242445658837572726160
Fixed Assets1111111000012
CWIP0000000000000
Investments0000051410000
Other Assets21233141445156787471726058
Total Assets22243242445658837572726160

Reserves and Borrowings Chart

Cash Flow

MonthMar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023
Cash from Operating Activity 00000-9-64-78125
Cash from Investing Activity 000000-0-0000-0
Cash from Financing Activity 0000087-47-6-10-4
Net Cash Flow00000-1-0-0-0231

Free Cash Flow

MonthMar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023
Free Cash Flow-10.00-11.00-17.00-25.00-25.00-18.00-17.00-26.00-27.00-23.00-18.00-16.00

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

MonthMar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023
Debtor Days1498565716680679054805825
Inventory Days220161177123133145174187215153100
Days Payable180534333816911753791211
Cash Conversion Cycle19085174205156132143146188216199114
Working Capital Days167107149166134125138139212258165123
ROCE %12%2%12%10%10%15%17%13%7%7%9%7%

Financial Efficiency Indicators Chart

Share Holding Pattern

MonthMar 2020Sep 2020Mar 2021Sep 2021Mar 2022Sep 2022Mar 2023Sep 2023Mar 2024
Promoters70.42%70.42%71.80%71.80%70.11%69.09%68.24%68.69%68.77%
FIIs0.00%0.00%0.00%0.00%0.00%0.85%0.85%1.33%1.33%
DIIs0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.89%0.89%
Public29.58%29.58%28.20%28.20%29.89%30.07%30.91%29.09%29.02%
No. of Shareholders17815610690126126146134151

Shareholding Pattern Chart

No. of Shareholders

This stock is not held by any mutual fund

ROCE Trend

EPS Trend

Key Financial Ratios

MonthMar 23Mar 22Mar 21Mar 20Mar 19
FaceValue10.0010.0010.0010.0010.00
Basic EPS (Rs.)1.201.060.250.551.17
Diluted EPS (Rs.)1.201.060.250.551.17
Cash EPS (Rs.)1.551.220.290.4510.11
Book Value[Excl.RevalReserv]/Share (Rs.)36.4235.3534.3034.05214.34
Book Value[Incl.RevalReserv]/Share (Rs.)36.4235.3534.3034.05214.34
Revenue From Operations / Share (Rs.)158.61124.6893.70124.561585.30
PBDIT / Share (Rs.)4.795.691.054.6669.71
PBIT / Share (Rs.)4.445.531.014.6268.94
PBT / Share (Rs.)1.541.450.360.5513.21
Net Profit / Share (Rs.)1.201.050.250.419.34
PBDIT Margin (%)3.014.561.123.734.39
PBIT Margin (%)2.794.431.073.704.34
PBT Margin (%)0.971.160.390.440.83
Net Profit Margin (%)0.750.840.260.330.58
Return on Networth / Equity (%)3.292.980.731.224.35
Return on Capital Employeed (%)9.9512.121.958.5615.26
Return On Assets (%)1.491.090.260.420.75
Long Term Debt / Equity (X)0.140.200.360.420.79
Total Debt / Equity (X)0.680.740.961.071.94
Asset Turnover Ratio (%)1.801.300.961.191.51
Current Ratio (X)2.191.862.132.141.55
Quick Ratio (X)1.110.961.060.850.71
Inventory Turnover Ratio (X)0.530.070.230.000.00
Interest Coverage Ratio (X)1.651.401.651.151.25
Interest Coverage Ratio (Post Tax) (X)1.411.261.391.101.17
Enterprise Value (Cr.)85.6999.9252.5457.630.00
EV / Net Operating Revenue (X)0.711.060.740.610.00
EV / EBITDA (X)23.7123.2666.0216.400.00
MarketCap / Net Operating Revenue (X)0.610.910.420.320.00
Price / BV (X)2.663.221.151.170.00
Price / Net Operating Revenue (X)0.610.910.420.320.00
EarningsYield0.010.010.010.010.00

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

Fair Value

Fair Value: ₹98.05

Calculation basis:

  • Fair value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100)
  • P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
  • Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance
  • Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
  • Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.

This formula allows us to gauge the fair value of the stock by analyzing its fundamental indicators.

Overvalued: 17.61% compared to the current price ₹119

Intrinsic Value: ₹127.92

Calculation basis:

  • Fair value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100) * (1 + EPS CAGR for Last 5 Years)
  • P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
  • Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
  • Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
  • Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.
  • EPS CAGR (Compound Annual Growth Rate): Represents the geometric mean growth rate of earnings per share over the last 5 years. It provides insight into the historical growth trajectory of the company's earnings.

This formula allows us to gauge the fair value of the stock by analyzing its fundamental indicators along with EPS growth.

Undervalued: 7.50% compared to the current price ₹119

Last 5 Year EPS CAGR: 30.47%

*Investments are subject to market risks

Strength and Weakness

StrengthWeakness
  1. The company has shown consistent growth in sales (85.46 cr) and profit (0.77 cr) over the years.
  1. The stock has a low average ROCE of 10.08%, which may not be favorable.
  2. The stock has a high average Working Capital Days of 156.92, which may not be favorable.
  3. The stock has a high average Cash Conversion Cycle of 162.33, which may not be favorable.
  4. The company has higher borrowings (22.08) compared to reserves (11.46), which may suggest financial risk.

Stock Analysis

  • Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Chandra Bhagat Pharma Ltd:
    1. Net Profit Margin: 0.75%
      • Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
    2. ROCE: 9.95% (Industry Average ROCE: 37.24%)
      • ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
    3. ✗ ROE%: 3.29% (Industry Average ROE: 27.13%)
      • ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
    4. Interest Coverage Ratio (Post Tax): 1.41
      • Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
    5. Quick Ratio: 1.11
      • Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
    6. ✓ Stock P/E: 76.7 (Industry average Stock P/E: 85.3)
      • Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
    7. ✓ Total Debt / Equity: 0.68
      • Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
    The current analysis is available for review. It's important to conduct thorough research and consider consulting with financial professionals before making any investment decisions.
    Stock Rating:

About the Company - Qualitative Analysis

Chandra Bhagat Pharma Ltd. is a Public Limited Listed company incorporated on 10/03/2003 and has its registered office in the State of Maharashtra, India. Company’s Corporate Identification Number(CIN) is L24230MH2003PLC139534 and registration number is 139534. Currently company belongs to the Industry of Pharmaceuticals. Company’s Total Operating Revenue is Rs. 94.08 Cr. and Equity Capital is Rs. 7.55 Cr. for the Year ended 31/03/2022.
INDUSTRYADDRESSCONTACT
Pharmaceuticals323-F Bhagat Bhuvan, Mumbai Maharashtra 400019compliancecbc@gmail.com
http://www.cbcpharma.com
Management
NamePosition Held
Mr. Hemant Chandravadan BhagatChairman & Managing Director
Mr. Pranav Hemant BhagatWhole Time Director
Mrs. Prachi Pranav BhagatDirector & CFO
Mr. Ravindra Gajanan AwatiIndependent Director
Ms. Abha Praveen DoshiIndependent Director

FAQ

What is the latest fair value of Chandra Bhagat Pharma Ltd?

The latest fair value of Chandra Bhagat Pharma Ltd is ₹98.05.

What is the Market Cap of Chandra Bhagat Pharma Ltd?

The Market Cap of Chandra Bhagat Pharma Ltd is 89.7 Cr..

What is the current Stock Price of Chandra Bhagat Pharma Ltd as on 22 May 2024?

The current stock price of Chandra Bhagat Pharma Ltd as on 22 May 2024 is ₹119.

What is the High / Low of Chandra Bhagat Pharma Ltd stocks in FY 2024?

In FY 2024, the High / Low of Chandra Bhagat Pharma Ltd stocks is ₹160/80.0.

What is the Stock P/E of Chandra Bhagat Pharma Ltd?

The Stock P/E of Chandra Bhagat Pharma Ltd is 76.7.

What is the Book Value of Chandra Bhagat Pharma Ltd?

The Book Value of Chandra Bhagat Pharma Ltd is 37.3.

What is the Dividend Yield of Chandra Bhagat Pharma Ltd?

The Dividend Yield of Chandra Bhagat Pharma Ltd is 0.00 %.

What is the ROCE of Chandra Bhagat Pharma Ltd?

The ROCE of Chandra Bhagat Pharma Ltd is 7.13 %.

What is the ROE of Chandra Bhagat Pharma Ltd?

The ROE of Chandra Bhagat Pharma Ltd is 3.36 %.

What is the Face Value of Chandra Bhagat Pharma Ltd?

The Face Value of Chandra Bhagat Pharma Ltd is 10.0.

About the Author

Author Avatar
Getaka

Getaka, CFA, a financial analyst with 15 years of experience in the industry. Getaka holds an MBA degree and the Chartered Financial Analyst designation, demonstrating his profound understanding of financial analysis and investment management. Throughout his career, he has conducted numerous financial analyses and due diligence processes for companies in the industry, and has a strong track record of identifying key trends and opportunities. He leverages his expertise to deliver a thorough financial analysis of a company, encompassing its financial performance, key ratios, future prospects, and risks. Getaka is committed to providing accurate, reliable, and trustworthy information to help readers make informed decisions about their finances and investments.

Disclaimer: This article is for informational purposes only and should not be construed as financial advice. The author is not a SEBI registered financial advisor and does not have any vested interest in Chandra Bhagat Pharma Ltd. Investors are advised to conduct their own due diligence and consult with a financial professional before making any investment decisions. The information provided in this article is based on publicly available data and the author's analysis, but it may not be comprehensive or up-to-date. The author and getaka.co.in are not responsible for any errors or omissions in the content. This article is not intended to promote any particular investment strategy or recommendation, and readers should consult with their own financial advisors before making any investment decisions. Data Source: NSE